PeptideCompareTeriparatide — EU research guide.
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34) that, unlike constantly elevated PTH, builds new bone when exposure is intermittent (pulsed) — the original bone-anabolic peptide that abaloparatide was later designed to improve on.
What is Teriparatide?
Teriparatide reproduces the first 34 amino acids of human PTH. Intermittent (pulsed) exposure paradoxically stimulates osteoblasts to build new bone, rather than triggering the bone breakdown seen with chronically elevated PTH.
What does the research show?
Authorised in the EU since 2003 for osteoporosis, teriparatide has extensive trial data showing reduced vertebral and non-vertebral fracture risk. It directly informed the design of abaloparatide, a related analogue with a more bone-selective receptor-binding profile and fewer off-target effects.
EU legal status
EMA-approved prescription medicine (Forsteo, and the biosimilar Terrosa) for osteoporosis, with a maximum lifetime treatment duration of 24 months due to a rodent osteosarcoma signal at high, prolonged doses.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Bone-pathway compounds across EU suppliers
COA-verified EU vendors · Updated monthly
References
- The original pivotal placebo-controlled trial (1,637 women, median 21 months). It shows fewer vertebral and non-vertebral fragility fractures with parathyroid hormone (1-34); it studied postmenopausal women only and is not evidence for any use outside diagnosed osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. DOIPubMed 11346808
- The VERO trial: teriparatide versus the bisphosphonate risedronate in women with severe osteoporosis, 24 months, double-blind. It found fewer new vertebral fractures with teriparatide; the reduction in non-vertebral fractures was not statistically significant. Concerns the licensed medicine, not vendor 'research' vials. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-240. DOIPubMed 29129436
- The official EU summary of product characteristics: indication, the 24-month lifetime maximum, the rat osteosarcoma statement, half-life of about 1 hour after subcutaneous injection, and storage (refrigerated at all times). This describes the licensed product, which vendor research material is not. European Medicines Agency. Forsteo (teriparatide): EPAR product information (summary of product characteristics). Source
- The EMA medicine page: authorised in the EU on 10 June 2003 for osteoporosis in postmenopausal women and men at increased fracture risk, and for glucocorticoid-associated osteoporosis. It confirms the two-year lifetime limit. European Medicines Agency. Forsteo (teriparatide): EPAR medicine page. Source
- The EMA page for Terrosa, authorised on 4 January 2017: a biosimilar of Forsteo (not a generic), meaning it was shown to be highly similar to the reference medicine. European Medicines Agency. Terrosa (teriparatide): EPAR medicine page (biosimilar of Forsteo). Source